New Market For Genentech's Gazyva: Follicular Lymphoma
This article was originally published in Scrip
Executive Summary
Roche AG unit Genentech Inc. won the FDA's approval to market Gazyva (obinutuzumab) as a treatment for follicular lymphoma, the most common type of indolent non-Hodgkin's lymphoma (NHL), accounting for about one in five cases of the disease.